Tiziano Lazzaretti Appointed as CFO to Drive Financial Strategy at NMS S.r.l.
NERVIANO, IT and BOSTON, Mass, November 2, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment […]
Nerviano Medical Sciences S.r.l. to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC 2023: Poster
Nerviano Medical Sciences Presents Preliminary, Encouraging Clinical Phase 1 Data for PARP-1 Selective Inhibitor at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics NERVIANO, IT and BOSTON, Mass, October 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned […]
Nerviano Medical Sciences S.r.l. : We are attending the 2023 BIO Europe partnering event in Munich, Germany.
We are attending the 2023 BIO Europe partnering event in Munich, Germany. NMS Group- Nerviano Medical Sciences will participate to the 2023 BIO Europe partnering event, which will be held in Munich from November 6th to 8th, 2023 and online from November 14th to 15th, 2023. We are looking forward to your […]
Nerviano Medical Sciences to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
NERVIANO, IT and BOSTON, Mass, October 2, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today it will […]
Nerviano Medical Sciences S.r.l. to present data on its ADC platform at the World ADC Summit 2023 in San Diego CA (Oct 16th-Oct 19th, 2023)
September 25th, 2023 Nerviano Medical Sciences S.r.l., a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2023 summit that will be held in San Diego (CA) from October 16th to October 19th, 2023, […]
Nerviano Medical Sciences S.r.l. partecipa alla European Biotech Week 2023 / Nerviano Medical Sciences S.r.l. participates in the European Biotech Week 2023
Nerviano Medical Sciences (NMS), una Biotech focalizzata sulla ricerca e sviluppo di farmaci Oncologici innovativi, partecipa alla Settimana Europea delle Biotecnologie (European Biotech Week – EBW), giunta quest’anno alla sua XI edizione. La EBW è una settimana di eventi e incontri in tutta Europa per raccontare le biotecnologie nei diversi settori di applicazione ad un pubblico vasto […]
Nerviano Medical Sciences S.r.l. announces preclinical data on NMS-P945, its novel proprietary payload-linker for ADC generation, published in Molecular Cancer Therapeutics
Nerviano, September 20, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A. and a clinical stage biotech, discovering and developing innovative therapies for the treatment of cancer, today announces the publication of preclinical data on NMS-P945 (link to article), its novel protease-cleavable thienoduocarmycin derivative payload-linker, with DNA damaging properties, in Molecular […]
Nerviano Medical Sciences S.r.l. names Alberto Ocana, PhD, as Global Clinical Lead
Nerviano Italy, 11 September 2023 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that Alberto Ocana PhD, has joined the Global Clinical Development Team as Global Clinical Lead, effective immediately. In this pivotal role, […]
Nerviano Medical Sciences Announces Enhanced US Executive Team: Terrence West, MBA, Expands Role as Chief Operating Officer
NERVIANO, IT and BOSTON, Mass., August 1, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the expansion of and transition in its executive team of its wholly owned U.S. […]
Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 in positive Relapsed or Refractory Acute Myeloid Leukemia
Nerviano 22 June 2023_Nerviano Medical Sciences Srl (NMS), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to announce the FDA Clearance of Investigational New Drug (IND) Application for NMS-03592088 (NMS-088), a novel, potent FLT3 inhibitor. NMS-088 is poised to transform the landscape of […]
